Axecap Investments LLC Has $3.43 Million Stock Holdings in Gilead Sciences, Inc. $GILD

Axecap Investments LLC substantially reduced its stake in Gilead Sciences, Inc. during the fourth quarter, selling 37% of its shares but still holding 27,935 shares valued at $3.43 million. Despite insider selling by CFO Andrew D. Dickinson and CEO Daniel Patrick O’day, institutional ownership remains high at 83.67%, and analysts maintain a “Moderate Buy” rating with a target price of $157.35. Gilead Sciences also reported strong quarterly earnings, exceeding estimates, and increased its quarterly dividend to $0.82 per share.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin